45th week of 2010 patent applcation highlights part 35 |
Patent application number | Title | Published |
20100284995 | Temperature sensitive mutants of matrix metalloproteases and uses thereof - Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components. | 2010-11-11 |
20100284996 | Assays for Detection of Von Willebrand Factor (vWF) Multimers and for Degradation of vWF by Agents Such as Adamts13 and Related Methods - Methods of analyzing the electrophoretic mobility distribution of von Willebrand factor (vWF) multimers include providing a sample medium comprising a plurality vWF multimers. The vWF multimers are electrophoretically separated by electrohoretic mobility in the sample medium by subjecting said sample medium to an electric field to provide separated vWF multimers. The separated vWF multimers in the sample medium are exposed to a light source to produce scattered light. The scattered light is detected, and the electrophoretic mobility distribution of the separated vWF multimers is determined from the detected scattered light. | 2010-11-11 |
20100284997 | DOSING REGIMEN OF ACTIVATED PROTEIN C AND VARIANTS HAVING REDUCED ANTICOAGULANT ACTIVITY - Recombinant activated protein C (APC) and APC variants with reduced anticoagulant activity were used to reduce mortality in murine models of sepsis. These models included endotoxemia and bacteremia models. We discovered that single or multiple bolus doses of APC, especially of APC variants such as RR230/231AA-APC, KKK192-194AAA-APC and 5A-APC (containing the combination of mutations present in the first two APC variants) given as a single bolus reduces 7-day mortality of mice given lethal doses of endotoxin. Administrations of a single bolus of 5A-APC after the initiation of sepsis also reduces mortality caused by LPS. 5A-APC with ≦8% of normal anticoagulant activity (which has reduced risk of bleeding) reduces mortality when given as two bolus administrations at 3 hours and then at 10 hours after initiation of bacterial infection, i.e. after onset of sepsis. This shows, first, that one or more bolus injections of APC or of APC variants, especially 5A-APC, can reduce mortality when given beginning hours after the onset of sepsis and, second, that it is not necessary to administer APC as a continuous infusion which is the current standard of practice because one or more bolus administrations can reduce mortality. Furthermore, dosages of approximately 0.06 to 0.4 mg/kg of APC and APC variants are identified to be sufficient to reduce mortality in sepsis. | 2010-11-11 |
20100284998 | FIBRIN SEALANT - A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application. | 2010-11-11 |
20100284999 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 2010-11-11 |
20100285000 | USE OF VEGFR-2 INHIBITORS FOR TREATING METASTATIC CANCER - The present application provides compositions and methods for treating metastatic cancer. Patients having or at risk of developing metastases may be treated. Compositions useful for the invention include VEGFR-2 specific inhibitors. | 2010-11-11 |
20100285001 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations - Disclosed are compositions and methods related to new targets for cancer treatment. | 2010-11-11 |
20100285002 | TREATMENT OR PREVENTION OF INFLAMMATION BY TARGETING CYCLIN D1 - In one aspect, the invention relates to the treatment and/or prevention of inflammation by inhibition of cyclin D1. In one embodiment, Th1-mediated inflammation is selectively inhibited or reduced by a method comprising administering an agent that inhibits cyclin D1. In another embodiment, an autoimmune disease or a disorder characterized by or involving a Th1 inflammatory response is treated or prevented in a subject by a method comprising administering to the subject an agent that inhibits cyclin D1. | 2010-11-11 |
20100285003 | THERAPEUTIC PEPTIDES AND USES THEREOF - The present invention is directed to a family of therapeutic peptides capable of modulating cytokine expression and/or stimulating the immune system of subject without producing or sustaining serious side-effects. Methods using the peptides to modulate cytokine expression in a subject, treat a disease, enhance vaccination, and stimulate a subject's immune system response are also disclosed. | 2010-11-11 |
20100285004 | Anti-CD38 human antibodies and uses thereof - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore | 2010-11-11 |
20100285005 | ANTI-CXCR4 ANTIBODIES - The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis. | 2010-11-11 |
20100285006 | Compositions of Kinase Inhibitors and Their Use for Treatment of Cancer and Other Diseases Related to Kinases - The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof. | 2010-11-11 |
20100285007 | DIFFERENTIAL DIAGNOSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - Provided are methods of diagnosing in a subject a type of B-cell chronic lymphocytic leukemia (B-CLL). Also provided are antibodies, including monoclonal antibodies, that specifically bind FCRL2, FCRL3 or FCRL5 and methods of treating B-CLL using the antibodies. | 2010-11-11 |
20100285008 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS - Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component. | 2010-11-11 |
20100285009 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 2010-11-11 |
20100285010 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 2010-11-11 |
20100285011 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION - The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine. | 2010-11-11 |
20100285012 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS - The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8). | 2010-11-11 |
20100285013 | PD-1 ANTIBODIES IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOF - The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer. | 2010-11-11 |
20100285014 | IMMUNOGLOBULIN FUSION PROTEINS - The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful. | 2010-11-11 |
20100285015 | TARGETING RECOMBINANT THERAPEUTICS TO CIRCULATING RED BLOOD CELLS - Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000 copies per red blood cell. Pharmaceutical compositions comprising these fusion proteins, and methods of delivering an anti-thrombotic agent to the surface of a red blood cell via delivery of these fusion proteins, and methods of treating or preventing thrombosis, tissue ischemia, acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease via administration of the fusion proteins or compositions comprising same are also provided. | 2010-11-11 |
20100285016 | PRO34128 nucleic acids - The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 2010-11-11 |
20100285017 | MATRIPTASE PROTEIN AND USES THEREOF - The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development. | 2010-11-11 |
20100285018 | ESTROGEN RECEPTORS AND METHODS OF USE - The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies. | 2010-11-11 |
20100285019 | Anti-IL-17F Antibodies and Methods of Use Thereof - This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2010-11-11 |
20100285020 | LEUKEMIC CELL CNS INFILTRATION CONTROLLED BY NOTCH-INDUCED CHEMOTAXIS - The present invention is directed to methods of preventing central nervous system leukemia, treating T-cell acute lymphoblastic leukemia, and treating immune system disorders associated with CCR7-CCL19 mediated signaling. Suitable therapeutic agents for inhibiting CCR7-CCL19 signaling and methods of identifying additional therapeutic agents useful in the methods of the present invention are also disclosed. | 2010-11-11 |
20100285021 | LIGANDS FOR USE IN THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HEMOSTASIS DISORDERS - The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII. | 2010-11-11 |
20100285022 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 2010-11-11 |
20100285023 | DETECTING CYP24 EXPRESSION LEVEL AS A MARKER FOR PREDISPOSITION TO CANCER - This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal. | 2010-11-11 |
20100285024 | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases - The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant. | 2010-11-11 |
20100285025 | ANTIBODIES SPECIFIC FOR THE C-TERMINAL REGULATORY DOMAIN OF EGFR AND THEIR USE - Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms. | 2010-11-11 |
20100285026 | PHOSPHORYLATION OF HISTONE H3 AT THREONINE 11 - A NOVEL EPIGENETIC MARK FOR TRANSCRIPTIONAL REGULATION - The present invention relates to a process for controlling at least one androgen receptor- (AR-) regulated mechanism in mammalian cells under histone-phosphorylating conditions, said process comprising allowing at least one inhibitor with specificity for at least one protein kinase C-related kinase (PRK) to act on said at least one PRK1 thereby modulating, preferably down-regulating, the activity of said at least one PRK and optionally blocking said at least one androgen receptor-regulated mechanism in said mammalian cells. | 2010-11-11 |
20100285027 | ANTIBODIES SPECIFIC FOR HUMAN HEPCIDIN - The present invention relates to antigen-binding proteins having specificity for hepcidin, and their use for treating and diagnosing diseases associated with hepcidin. | 2010-11-11 |
20100285028 | METHODS OF TREATING COAGULOPATHY - The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an agent can be, for example, a neuraminidase. | 2010-11-11 |
20100285029 | Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies - The present invention relates to novel compositions and preparations that are effective antifungal agents, and a novel antibody which can be incorporated into the compositions and preparations. | 2010-11-11 |
20100285030 | Antibodies to Ox-2/Cd200 and Uses Thereof - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 2010-11-11 |
20100285031 | Hox Compositions and Methods - The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject. | 2010-11-11 |
20100285032 | ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) IN BONE AND CARTILAGE FORMATION AND METHODS AND COMPOSITIONS RELATING TO SAME - ERRγ is expressed in bone and cartilage in vivo and osteoblastic and chondrocytic cells in vitro. ERRγ is a transcriptional activator of an osteoblast-associated osteopontin (OPN) and chondrocyte-associated (Sox9) gene in osteoblasts and chondrocytes respectively. Knockdown of ERRγ expression by antisense oligonucleotide strategies in osteoblastic cell cultures reduces alkaline phosphatase activity. Together these findings indicate that ERRγ is expressed in and plays a functional role in bone and cartilage. The results also indicate that agonists and antagonists of ERRγ may be useful as therapeutic agents in a wide variety of diseases affecting bones and joints. | 2010-11-11 |
20100285033 | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF - Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders. | 2010-11-11 |
20100285034 | METHOD - Described are methods of separating viable cells, apoptotic cells and dead cells and antibodies or use in such methods. The antibodies may also be used in treatment of inflammatory disease, cancer and in wound healing. | 2010-11-11 |
20100285035 | High Affinity Antibody Antagonists of Interleukin-13 Receptor Alpha 1 - High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. | 2010-11-11 |
20100285036 | Anti-CD100 Neutralizing Antibodies and Methods of Using the Same - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100. | 2010-11-11 |
20100285037 | ANTIBODIES TO CLL-1 - Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1. | 2010-11-11 |
20100285038 | Factor Involved in Metastasis and Uses Thereof - The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell motility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1. | 2010-11-11 |
20100285039 | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells - Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer cells that increases the resistance of the cancer cells to CTL mediated cytolysis and to Fas induced cell death. It is believed that blocking the transmission of the anti-apoptotic signal by B7-H1 increases the susceptibility of the cancer cells to apoptosis and CTL cytolysis thereby enhancing the death of cancer cells. Preferred compounds or B7-H1 antagonists include antibodies that bind to B7-H1, B7-H1 receptors, or ligands of B7-H1 such as PD-I or B7-1. Additional B7-H1 antagonists include small molecules, for example small molecules that bind the cytoplasmic portion of B7-H1 or the extracellular portion of B7-H1 and inhibit, reduce, block or interfere with B7-H1 signal transduction. Methods for treating one or more symptoms associated with cancer or hyperproliferation are also provided. | 2010-11-11 |
20100285040 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting - Disclosed are methods of enhancing immune responses. Such methods involve the administration of vaccine compositions to different tissues to elicit an enhanced immune response. The enhanced response arises from the vaccination and boosting route of administration in two separate patient tissues, for example, by first administering a priming vaccination into skin and later administering a boost vaccination in muscle. In each case, priming and boosting, the administration of the vaccine composition is preferably carried out using contemporaneous electroporation-assisted delivery of the antigenic agent. | 2010-11-11 |
20100285041 | Class A Oligonucleotides with Immunostimulatory Potency - The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity. | 2010-11-11 |
20100285042 | METHODS OF ENHANCING ADJUVATICITY OF VACCINE COMPOSITIONS - The immunogenicity of vaccines is enhanced by co-administering a synthetic glycolipid, designated PBS-57, with the vaccine. PBS-57 has the ability to stimulate both a cell-mediated and humoral immune response. Co-administration of PBS-57 with a vaccine may be used in methods to stimulate one or more of a humoral immune response, a CD4+ T cell response, and a CD8+ cytotoxic T cell response. | 2010-11-11 |
20100285043 | MITE ANTIGENIC RICE - An objective of the present invention is to provide methods for accumulating in rice seeds a partial peptide of a mite antigen protein comprising several T cell epitopes, or a mite antigen peptide that has been modified to not form a conformation to be recognized as an antigen, and plants which have accumulated these peptides. | 2010-11-11 |
20100285044 | METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS - A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation. | 2010-11-11 |
20100285045 | Novel Neurotrophic Factor Protein and Uses Thereof - The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes. | 2010-11-11 |
20100285046 | Nontoxic ricin mutant compositions and methods - Disclosed are nontoxic ricin mutants and uses in connection with vaccines and cancer therapy. | 2010-11-11 |
20100285047 | THERAPEUTICS AND DIAGNOSTICS FOR GROUP A STREPTOCOCCI - Immunogenic compositions and vaccines are described comprising GAS Markers. Methods for detecting GAS diseases in a subject are also described comprising measuring GAS markers in a sample from the subject. The invention further provides kits for carrying out the methods of the invention and therapeutic applications for GAS diseases employing GAS markers, polynucleotides encoding the markers, and/or binding agents for the markers. | 2010-11-11 |
20100285048 | USE OF FLAGELLIN IN THE IMMUNOTHERAPY OF YERSINIA PESTIS - The invention provides a fusion protein comprising a flagellin adjuvant and a | 2010-11-11 |
20100285049 | Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method - The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such as | 2010-11-11 |
20100285050 | Compositions and Methods - The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same. | 2010-11-11 |
20100285051 | VACCINE - A component for a HIV vaccine comprising:
| 2010-11-11 |
20100285052 | Chemically Programmable Immunity - Methods and compositions for immediately immunizing an individual against any molecule or compound are provided. The present invention is directed to an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target. The second binding sites are preferably thiolated aptamers that have the benefit of increased stability, resistance to degradation and longer circulating half life. Methods of making and using pharmaceutical compositions including immunity linker molecules having a thiolated aptamer are also provided. | 2010-11-11 |
20100285053 | Immunosuppressive Extract Of Cordyceps Sinensis And Uses Thereof - The present invention described herein relates to aqueous extracts of | 2010-11-11 |
20100285054 | Antimicrobial Composition Comprising Fungal Extract, Process for Producing Fungal Extract and Method for Protecting Organisms - The present invention is directed to a fungal extract comprising antimicrobial activity. More specifically, the fungus used belongs to the family Polyporaceae, especially genus | 2010-11-11 |
20100285055 | Activation of natural killer (NK) cells and methods of use - The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal. | 2010-11-11 |
20100285056 | Baculovirus-Based Vaccines - The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine. | 2010-11-11 |
20100285057 | HEAT TREATED BACTERINS, AND EMULSION VACCINES PREPARED FROM SUCH HEAT TREATED BACTERINS - Heat treated bacterins, a method of producing heat treated bacterins, and porcine emulsion vaccines prepared from such heat treated bacterins are disclosed. | 2010-11-11 |
20100285058 | DNA VACCINE FOR TREATING OR PREVENTING CERVICAL CANCER COMPRISING A GENE ENCODING HPV PROTEIN - Disclosed herein is a DNA vaccine for treating cervical cancer including an E5 gene of human papillomavirus (HPV). Also, disclosed is a combination DNA vaccine for preventing and treating cervical cancer including a gene encoding HPV L1 and/or L2 along with the HPV E5 gene. | 2010-11-11 |
20100285059 | Cytomegalovirus Vaccines and Methods of Production - Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed. | 2010-11-11 |
20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS - The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen. | 2010-11-11 |
20100285061 | DNA VACCINATION PROTOCOLS - This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia. | 2010-11-11 |
20100285062 | COMBINED MUCOSAL AND PARENTERAL IMMUNIZATION AGAINST HIV - HIV antigens are mucosally administered in one or more priming immunization(s), and then HIV antigens are parenterally administered in one or more boosting immunization(s). Thus the invention provides a method for raising an immune response in a patient, comprising: (i) administering a HIV antigen to the patient via a mucosal route; and then (ii) administering a HIV antigen to the patient via a parenteral route. The antigens will typically be adjuvanted. Preferred mucosal immunizations are via the intranasal route using a detoxified mutant of | 2010-11-11 |
20100285063 | NOVEL CANINE INFLUENZA VIRUS AND VACCINE THEREFORE - Novel influenza viruses A/Canine/Korea/01/07 (H3N2), A/Canine/Korea/02/07 (H3N2) and A/Canine/Korea/03/07 (H3N2) are disclosed. A vaccine composition comprising at least one of the viruses, a method for preventing or treating diseases resulting from influenza virus infection by administering the vaccine composition, and an assay kit for detecting the viruses are also disclosed. | 2010-11-11 |
20100285064 | ADJUVANT COMPOSITION FOR VACCINE - The present invention provides a | 2010-11-11 |
20100285065 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid. | 2010-11-11 |
20100285066 | CANINE LEISHMANIA VACCINE - The present invention provides vectors that contain and express in vivo | 2010-11-11 |
20100285067 | INTERFERON-BETA PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME | 2010-11-11 |
20100285068 | METHOD FOR THE INTERNALIZATION OF NON-INVASIVE BACTERIA IN EUKARYOTE CELLS - The present invention relates to the use of adenylate cyclase toxin (ACT), or a functionally equivalent variant thereof, as an inducing agent for the internalization of non-invasive bacteria in eukaryotic cells. Due to ACT, said non-invasive bacterium can move through the plasma membrane of a eukaryotic cell and transfer plasmid DNA to said cell, which is useful for releasing or introducing molecules of therapeutic interest, for example, antigens, in the interior of the eukaryotic cell, thereby triggering the immune response. | 2010-11-11 |
20100285069 | MENINGOCOCCAL VACCINE FORMULATIONS - A dual formulation for vaccines against | 2010-11-11 |
20100285070 | POLYNUCLEOTIDES OF HAEMOPHILUS PARASUIS AND ITS USE - The present invention relates to | 2010-11-11 |
20100285071 | PURIFICATION OF HER-2 VARIANTS - The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), C) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein which for which the purification process has been especially adapted, as well as means for the preparation of the variant. | 2010-11-11 |
20100285072 | Method for Producing Dendritic Cells - The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection. | 2010-11-11 |
20100285073 | A MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF - The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease. | 2010-11-11 |
20100285074 | PHENOXYALKYLCARBOXYLIC ACID DERIVATIVES IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or prodrugs thereof: | 2010-11-11 |
20100285075 | Novel Hemioxalate Salt of Eletriptan - The present invention relates to novel hemioxalate salt of eletriptan, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention relates to solid forms of eletriptan hemioxalate, processes for preparation, pharmaceutical compositions, and method of treating thereof. The solid form of eletriptan hemioxalate is useful for preparing eletriptan free base or a pharmaceutically acceptable salt thereof, particularly eletriptan hydrobromide, in high purity. The present invention also provides a process for preparing substantially pure eletriptan hydrobromide using eletriptan hemioxalate. | 2010-11-11 |
20100285076 | FLUID COSMETIC COMPOSITION COMPRISING A MONOALCOHOL - The present invention relates to the field of making up and/or caring for the skin and is targeted in particular at providing a fluid care and/or make-up cosmetic composition in the form of a water-in-oil emulsion dedicated to the skin comprising a fatty phase, an aqueous phase and at least one dimethicone copolyol, the aqueous phase forming 40 to 60% by weight, with respect to the total weight of the said composition, and comprising at least 5% by weight, with respect to the total weight of the composition, of at least one C | 2010-11-11 |
20100285077 | COSMETIC COMPOSITION COMPRISING HYDROXYMETHIONINE AND 3-AMINOPROPANESULFONIC ACID - The present invention relates to cosmetic compositions comprising an association of hydroxymethionine and 3-aminopropanesulfonic acid, and a cosmetic method for the skin. These compositions are intended to prevent and/or treat the signs of the cutaneous ageing such as the sagging of the cutaneous and subcutaneous tissue, the loss of cutaneous elasticity and atony of the texture of the skin, the loss of firmness and tonicity, dermal atrophy and loss of density, wrinkle, little wrinkle, crack. | 2010-11-11 |
20100285078 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis and a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2010-11-11 |
20100285079 | METHOD FOR PRODUCING A COSMETIC PREPARATION - Provided is a method of producing a cosmetic by molding a powder composition under pressure, the method including: applying a vibration having a frequency of 10 to 40 kHz and an amplitude of 10 to 100 μm to a powder composition while the powder composition is molded under pressure, the powder composition containing: (A) a powder having an average particle size of 0.1 to 300 μm; (B) an oil which is liquid at 25° C.; and (C) an oil which is solid at 25° C., in which: the content of the component (A) is 75 to 95 % by mass; and a mass ratio of the component (B) to the component (C) “(B):(C)” is 6:4 to 9.5:0.5. | 2010-11-11 |
20100285080 | COSMETIC TREATMENT SYSTEM AND METHODS - A cosmetic treatment system is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from | 2010-11-11 |
20100285081 | Bactericidal Nanofibers, and Methods of Use Thereof - One aspect of the invention relates to an antimicrobial fiber formed from an electroprocessed blend of at least one polymer, at least one antimicrobial agent, and at least one crosslinker. Another aspect of the invention relates to an antimicrobial fiber formed from an electroprocessed blend of at least one polymer and at least one crosslinker, which is then coated with an antimicrobial compound or antimicrobial polymer. | 2010-11-11 |
20100285082 | Integrated Biosensor and Simulation System for Diagnosis and Therapy - BioMEMS/NEMS appliance biologically monitors an individual, using biosensors to detect cellular components. Data is simulated or analyzed using systems-biology software, which provides diagnostic or therapeutic guidance. | 2010-11-11 |
20100285083 | DRUG DELIVERY SYSTEM - It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective concentrations to local lesional sites in a body and allows the use of drugs for which it has thus far been difficult to achieve effective local concentrations for a variety of reasons and drugs which have been difficult to use due to adverse effects on tissues that are not sites of action. The present invention provides a drug delivery system comprising an indwelling medical device on which a biocompatible material having target molecules on its surface has been coated, and target-recognizing nanocarriers (e.g., bio-nanocapsules, liposomes, liposome preparations, and nanoparticles) in which drugs are encapsulated and which have target-recognizing molecules capable of specifically binding to the target molecules. | 2010-11-11 |
20100285084 | Antimicrobial coatings for medical devices and methods for making and using them - Embodiments of the invention provide methods for using compositions to inhibit microbial growth on a surface of a medical device having the composition applied thereto, to medical devices having the composition applied to a surface thereof and to methods for using the compositions to coat medical devices. | 2010-11-11 |
20100285085 | BALLOON COATING WITH DRUG TRANSFER CONTROL VIA COATING THICKNESS - A coated medical device, such a balloon or stent. The coating includes a therapeutic agent having a thickness of the coating is between about 1.5 to 10 μm and less than 30% of the coating remains on the balloon post delivery to a vessel. | 2010-11-11 |
20100285086 | Biomimetic Extracellular Matrices - The present invention is directed to hydrogel compositions for biotechnology applications. Specifically, the invention provides hydrogels mimicking the ECM and uses thereof. | 2010-11-11 |
20100285087 | SINGLE PHENOTHIAZINE ENANTIOMERS AS AGENTS FOR THE PREVENTION OF BONE LOSS - Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution. | 2010-11-11 |
20100285088 | Tissue Adhesives and Sealants and Method for Their Use - Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses. | 2010-11-11 |
20100285089 | Medical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In particular, disclosed herein is a drug delivery device comprising a balloon-expandable intraluminal stent, and a pharmaceutical agent-containing coating, wherein the coating comprises a biocompatible polyfluoro copolymer that comprises about eighty-five weight percent vinylidinefluoride copolymerized with about fifteen weight percent hexafluoropropylene and a pharmaceutical agent intermixed with said polyfluoro copolymer. | 2010-11-11 |
20100285090 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 2010-11-11 |
20100285091 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 2010-11-11 |
20100285092 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 2010-11-11 |
20100285093 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 2010-11-11 |
20100285094 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions. | 2010-11-11 |